ProMIS Neurosciences Presents Data From PMN310 Phase1a Clinical Trial At The 17th Clinical Trials On Alzheimer's Disease Conference; Results Indicated PMN310 Was Generally Well-Tolerated And Monthly Dosing Can Provide CSF Levels Adequate For Target...

BenzingaOct 30 08:10 ET

Express News | ProMIS Neurosciences Inc - Pmn310 Generally Well-Tolerated, Monthly Dosing Adequate for Target Engagement

ReutersOct 30 08:00 ET

Express News | ProMIS Neurosciences Presents Positive Data From Pmn310 Phase1a Clinical Trial at the 17TH Clinical Trials on Alzheimer’s Disease Conference

ReutersOct 30 08:00 ET

ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now

Yahoo FinanceOct 13 14:58 ET

ProMIS Neurosciences Names Neil Warma Permanent CEO

TipRanksOct 10 17:01 ET

Express News | ProMIS Neurosciences Inc: Appointed Neil Warma as the President & Chief Executive Officer of Co

ReutersOct 10 16:45 ET